Total Payments
$586,209
2024 Payments
$6,160
Companies
35
Transactions
914
Medicare Patients
4,270
Medicare Billing
$438,432
Payment Breakdown by Category
Other$418,495 (71.4%)
Consulting$56,445 (9.6%)
Education$47,811 (8.2%)
Travel$38,121 (6.5%)
Food & Beverage$25,200 (4.3%)
Gifts$137.26 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $418,495 | 212 | 71.4% |
| Consulting Fee | $56,445 | 21 | 9.6% |
| Education | $47,811 | 27 | 8.2% |
| Travel and Lodging | $38,121 | 111 | 6.5% |
| Food and Beverage | $25,200 | 542 | 4.3% |
| Gift | $137.26 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| United Therapeutics Corporation | $211,972 | 239 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $132,877 | 123 | $0 (2023) |
| Actelion Pharmaceuticals US, Inc. | $98,479 | 135 | $0 (2024) |
| INTUITIVE SURGICAL, INC. | $65,108 | 75 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $27,293 | 44 | $0 (2023) |
| Insmed, Inc. | $19,579 | 21 | $0 (2023) |
| Gilead Sciences, Inc. | $15,724 | 42 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $9,076 | 54 | $0 (2023) |
| Pulmonx Corporation | $1,749 | 10 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,502 | 48 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,160 | 30 | Actelion Pharmaceuticals US, Inc. ($3,972) |
| 2023 | $53,203 | 70 | Intuitive Surgical, Inc. ($22,381) |
| 2022 | $85,029 | 76 | Boehringer Ingelheim Pharmaceuticals, Inc. ($29,162) |
| 2021 | $114,884 | 97 | United Therapeutics Corporation ($64,642) |
| 2020 | $61,053 | 52 | Boehringer Ingelheim Pharmaceuticals, Inc. ($24,886) |
| 2019 | $87,960 | 139 | Boehringer Ingelheim Pharmaceuticals, Inc. ($24,609) |
| 2018 | $69,765 | 211 | United Therapeutics Corporation ($24,792) |
| 2017 | $108,154 | 239 | United Therapeutics Corporation ($40,931) |
All Payment Transactions
914 individual payment records from CMS Open Payments — Page 1 of 37
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $26.23 | General |
| Category: NEUROLOGY | ||||||
| 11/14/2024 | Ambu Inc. | — | Food and Beverage | Cash or cash equivalent | $79.63 | General |
| 11/13/2024 | Pulmonx Corporation | CHARTIS CATHETER (Device), ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | Food and Beverage | In-kind items and services | $147.61 | General |
| Category: PULMONOLOGY | ||||||
| 08/27/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $122.40 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/26/2024 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $137.20 | General |
| 08/05/2024 | Pulmonx Corporation | CHARTIS CATHETER (Device), ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | Food and Beverage | In-kind items and services | $63.44 | General |
| Category: PULMONOLOGY | ||||||
| 06/30/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $30.70 | General |
| Category: Cardiology | ||||||
| 06/30/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $29.58 | General |
| 06/29/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $64.97 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 06/06/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $33.93 | General |
| Category: NEUROLOGY | ||||||
| 06/04/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $22.83 | General |
| Category: SURGERY | ||||||
| 05/23/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $126.50 | General |
| Category: Cardiology | ||||||
| 05/19/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $105.83 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 05/17/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Consulting Fee | Cash or cash equivalent | $2,725.00 | General |
| Category: Cardiology | ||||||
| 05/08/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Travel and Lodging | In-kind items and services | $342.03 | General |
| Category: Cardiology | ||||||
| 05/08/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: Cardiology | ||||||
| 05/08/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Cardiology | ||||||
| 05/07/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $71.30 | General |
| Category: Cardiology | ||||||
| 05/07/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $25.30 | General |
| Category: Cardiology | ||||||
| 04/24/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Travel and Lodging | In-kind items and services | $405.70 | General |
| Category: Cardiology | ||||||
| 04/17/2024 | United Therapeutics Corporation | ORENITRAM (Drug), TYVASO, REMODULIN | Food and Beverage | In-kind items and services | $77.47 | General |
| Category: Pulmonary Arterial Hypertension | ||||||
| 04/12/2024 | United Therapeutics Corporation | — | Travel and Lodging | In-kind items and services | $281.82 | General |
| 03/26/2024 | Pulmonx Corporation | CHARTIS CATHETER (Device), ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | Food and Beverage | In-kind items and services | $67.30 | General |
| Category: PULMONOLOGY | ||||||
| 03/05/2024 | United Therapeutics Corporation | — | Travel and Lodging | In-kind items and services | $632.73 | General |
| 03/05/2024 | United Therapeutics Corporation | — | Travel and Lodging | In-kind items and services | $35.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 28 | 1,360 | 1,547 | $546,916 | $101,695 |
| 2022 | 17 | 919 | 1,275 | $459,263 | $117,233 |
| 2021 | 21 | 968 | 1,256 | $485,877 | $111,438 |
| 2020 | 23 | 1,023 | 1,275 | $423,727 | $108,065 |
Total Patients
4,270
Total Services
5,353
Medicare Billing
$438,432
Procedure Codes
89
All Medicare Procedures & Services
89 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 246 | 363 | $125,443 | $30,971 | 24.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 77 | 77 | $44,821 | $9,386 | 20.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 62 | 63 | $44,971 | $8,842 | 19.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 74 | 114 | $27,806 | $7,083 | 25.5% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 161 | 161 | $49,920 | $7,041 | 14.1% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 136 | 136 | $43,112 | $5,739 | 13.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 31 | 31 | $27,357 | $5,297 | 19.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 18 | 35 | $14,889 | $3,395 | 22.8% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 151 | 153 | $32,379 | $3,046 | 9.4% |
| 31629 | Needle biopsy of windpipe cartilage, airway, and/or lung using an endoscope | Facility | 2023 | 23 | 23 | $13,570 | $2,993 | 22.1% |
| 95810 | Sleep study in sleep lab (6 years or older) | Facility | 2023 | 28 | 28 | $10,416 | $2,484 | 23.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 19 | 19 | $8,383 | $2,007 | 23.9% |
| 31627 | Computer-assisted image-guided navigation of lung airways using an endoscope | Facility | 2023 | 24 | 24 | $7,325 | $1,861 | 25.4% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 53 | 53 | $17,963 | $1,591 | 8.9% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Facility | 2023 | 20 | 20 | $7,760 | $1,564 | 20.2% |
| J2545 | Pentamidine isethionate, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per 300 mg | Office | 2023 | 20 | 22 | $9,827 | $1,522 | 15.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 15 | 15 | $6,582 | $1,350 | 20.5% |
| 31654 | Exam of lung airways with diagnostic or therapeutic procedure on growths using an endoscope and ultrasound | Facility | 2023 | 24 | 24 | $5,136 | $1,284 | 25.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 13 | 13 | $3,391 | $844.87 | 24.9% |
| 94070 | Test to measure lung airway sensitivity | Office | 2023 | 16 | 16 | $5,824 | $766.08 | 13.2% |
| 94799 | Other service or procedure on lung | Office | 2023 | 12 | 12 | $4,656 | $675.12 | 14.5% |
| 95806 | Sleep study including heart rate, breathing, airflow, and effort | Office | 2023 | 17 | 17 | $8,517 | $641.94 | 7.5% |
| 94642 | Inhalation treatment for pneumonia | Office | 2023 | 21 | 23 | $6,095 | $560.51 | 9.2% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 33 | 33 | $6,435 | $299.64 | 4.7% |
| 94640 | Inhalation treatment for airway obstruction or sputum production | Office | 2023 | 30 | 35 | $3,185 | $246.40 | 7.7% |
About Dr. Abubakr Bajwa, M.D
Dr. Abubakr Bajwa, M.D is a Pulmonary Disease healthcare provider based in Jacksonville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/22/2005. The National Provider Identifier (NPI) number assigned to this provider is 1467442392.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Abubakr Bajwa, M.D has received a total of $586,209 in payments from pharmaceutical and medical device companies, with $6,160 received in 2024. These payments were reported across 914 transactions from 35 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($418,495).
As a Medicare-enrolled provider, Bajwa has provided services to 4,270 Medicare beneficiaries, totaling 5,353 services with total Medicare billing of $438,432. Data is available for 4 years (2020–2023), covering 89 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Jacksonville, FL
- Active Since 10/22/2005
- Last Updated 09/05/2023
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1467442392
Products in Payments
- OFEV (Drug) $69,678
- Da Vinci Surgical System (Device) $60,958
- TYVASO (Drug) $54,419
- UPTRAVI (Drug) $43,535
- ORENITRAM (Drug) $42,378
- Adempas (Drug) $27,293
- OPSUMIT MACITENTAN (Drug) $26,502
- NONE (Drug) $19,217
- Arikayce (Drug) $15,499
- Letairis (Drug) $15,352
- REMODULIN (Drug) $12,891
- FASENRA (Drug) $7,999
- OPSUMIT (Drug) $6,961
- DA VINCI SP (Device) $4,150
- Pulmonx Endobronchial Valve EBV (Device) $1,142
- FASENRA (Biological) $523.50
- CHARTIS CATHETER (Device) $509.53
- BEVESPI AEROSPHERE (Drug) $374.62
- Esbriet (Biological) $308.27
- SPIRIVA RESPIMAT (Drug) $262.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Jacksonville
Jorge Mallea, Md, MD
Pulmonary Disease — Payments: $206,363
Pulmonary Disease $206,363
Charles Burger, Md, MD
Pulmonary Disease — Payments: $141,922
Pulmonary Disease $141,922
Dr. Sebastian Fernandez-Bussy, M.d, M.D
Pulmonary Disease — Payments: $125,148
Pulmonary Disease $125,148
Dr. Daniel Wyzan, Md, MD
Pulmonary Disease — Payments: $113,878
Pulmonary Disease $113,878
Peter Nassar, Md, MD
Pulmonary Disease — Payments: $80,367
Pulmonary Disease $80,367
Mitchell Rothstein, Md, MD
Pulmonary Disease — Payments: $64,712
Pulmonary Disease $64,712